

# 2019 Future of Alcohol Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/29BCFD1AE46EN.html>

Date: February 2019

Pages: 120

Price: US\$ 2,199.00 (Single User License)

ID: 29BCFD1AE46EN

## Abstracts

The global demand for Alcohol Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Alcohol Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Alcohol Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

### Alcohol Addiction Report Description-

The 2019 pipeline study on Alcohol Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Alcohol Addiction pipeline compounds.

The Alcohol Addiction pipeline guide presents information on all active drugs currently being developed for Alcohol Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Alcohol Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Alcohol Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Alcohol Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Alcohol Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Alcohol Addiction pipeline report includes-

An overview of Alcohol Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Alcohol Addiction pipeline

Company wise list of Alcohol Addiction pipeline

Mechanism of Action wise Alcohol Addiction pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Alcohol Addiction pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Alcohol Addiction pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Alcohol Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. GLOBAL ALCOHOL ADDICTION PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

### 3. EXECUTIVE SUMMARY

- 3.1 Alcohol Addiction Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
  - 3.2.1 Pre-clinical
  - 3.2.2 Discovery
  - 3.2.3 Phase
  - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
  - 3.3.1 Phase
  - 3.3.2 Pre-registration
- 3.4 Companies involved in Alcohol Addiction pipeline, H1- 2019
- 3.5 Mechanism of Action wise Alcohol Addiction Pipeline Candidates

### 4 ABBVIE INC ALCOHOL ADDICTION PIPELINE DETAILS

- 4.1 AbbVie Inc Business Profile
- 4.2 AbbVie Inc Alcohol Addiction Drug Details
- 4.3 Drug Snapshot
  - 4.3.1 Originator
  - 4.3.2 Collaborator/Co-Developer
  - 4.3.3 Route of Administration
  - 4.3.4 Orphan Drug/Fast Track/Special Designation
  - 4.3.5 Geography
  - 4.3.6 Type of Molecular Entity
  - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5 ADDEX THERAPEUTICS LTD ALCOHOL ADDICTION PIPELINE DETAILS**

- 5.1 Addex Therapeutics Ltd Business Profile
- 5.2 Addex Therapeutics Ltd Alcohol Addiction Drug Details
- 5.3 Drug Snapshot
  - 5.3.1 Originator
  - 5.3.2 Collaborator/Co-Developer
  - 5.3.3 Route of Administration
  - 5.3.4 Orphan Drug/Fast Track/Special Designation
  - 5.3.5 Geography
  - 5.3.6 Type of Molecular Entity
  - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6 ADIAL PHARMACEUTICALS LLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 6.1 Adial Pharmaceuticals LLC Business Profile
- 6.2 Adial Pharmaceuticals LLC Alcohol Addiction Drug Details
- 6.3 Drug Snapshot
  - 6.3.1 Originator
  - 6.3.2 Collaborator/Co-Developer
  - 6.3.3 Route of Administration
  - 6.3.4 Orphan Drug/Fast Track/Special Designation
  - 6.3.5 Geography
  - 6.3.6 Type of Molecular Entity
  - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7 AMYGDALA NEUROSCIENCES INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 7.1 Amygdala Neurosciences Inc Business Profile
- 7.2 Amygdala Neurosciences Inc Alcohol Addiction Drug Details
- 7.3 Drug Snapshot
  - 7.3.1 Originator
  - 7.3.2 Collaborator/Co-Developer
  - 7.3.3 Route of Administration
  - 7.3.4 Orphan Drug/Fast Track/Special Designation
  - 7.3.5 Geography
  - 7.3.6 Type of Molecular Entity
  - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8 ARBOR PHARMACEUTICALS LLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 8.1 Arbor Pharmaceuticals LLC Business Profile
- 8.2 Arbor Pharmaceuticals LLC Alcohol Addiction Drug Details
- 8.3 Drug Snapshot
  - 8.3.1 Originator
  - 8.3.2 Collaborator/Co-Developer
  - 8.3.3 Route of Administration
  - 8.3.4 Orphan Drug/Fast Track/Special Designation
  - 8.3.5 Geography
  - 8.3.6 Type of Molecular Entity
  - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9 ASSUAGE PHARMACEUTICALS INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 9.1 Assuage Pharmaceuticals Inc Business Profile
- 9.2 Assuage Pharmaceuticals Inc Alcohol Addiction Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

## **10 ASTRAEA THERAPEUTICS LLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 10.1 Astraea Therapeutics LLC Business Profile
- 10.2 Astraea Therapeutics LLC Alcohol Addiction Drug Details
- 10.3 Drug Snapshot
  - 10.3.1 Originator
  - 10.3.2 Collaborator/Co-Developer
  - 10.3.3 Route of Administration
  - 10.3.4 Orphan Drug/Fast Track/Special Designation
  - 10.3.5 Geography
  - 10.3.6 Type of Molecular Entity
  - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

## **11 ASTRAZENECA PLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 11.1 AstraZeneca Plc Business Profile
- 11.2 AstraZeneca Plc Alcohol Addiction Drug Details
- 11.3 Drug Snapshot
  - 11.3.1 Originator
  - 11.3.2 Collaborator/Co-Developer
  - 11.3.3 Route of Administration
  - 11.3.4 Orphan Drug/Fast Track/Special Designation
  - 11.3.5 Geography



- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

## **12 BIOCORRX INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 12.1 BioCorRx Inc Business Profile
- 12.2 BioCorRx Inc Alcohol Addiction Drug Details
- 12.3 Drug Snapshot
  - 12.3.1 Originator
  - 12.3.2 Collaborator/Co-Developer
  - 12.3.3 Route of Administration
  - 12.3.4 Orphan Drug/Fast Track/Special Designation
  - 12.3.5 Geography
  - 12.3.6 Type of Molecular Entity
  - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13 BIONEX PHARMACEUTICALS LLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 13.1 Bionex Pharmaceuticals LLC Business Profile
- 13.2 Bionex Pharmaceuticals LLC Alcohol Addiction Drug Details
- 13.3 Drug Snapshot
  - 13.3.1 Originator
  - 13.3.2 Collaborator/Co-Developer
  - 13.3.3 Route of Administration
  - 13.3.4 Orphan Drug/Fast Track/Special Designation
  - 13.3.5 Geography
  - 13.3.6 Type of Molecular Entity
  - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

### 13.7 Latest Drug Developments

## **14 BIOPROJET SCR ALCOHOL ADDICTION PIPELINE DETAILS**

### 14.1 Bioprojet SCR Business Profile

### 14.2 Bioprojet SCR Alcohol Addiction Drug Details

### 14.3 Drug Snapshot

#### 14.3.1 Originator

#### 14.3.2 Collaborator/Co-Developer

#### 14.3.3 Route of Administration

#### 14.3.4 Orphan Drug/Fast Track/Special Designation

#### 14.3.5 Geography

#### 14.3.6 Type of Molecular Entity

#### 14.3.7 Current Status

### 14.4 Drug Overview

### 14.5 Drug Mechanism of Action

### 14.6 Clinical/Pre-clinical Trial Details

### 14.7 Latest Drug Developments

## **15 CHRONOS THERAPEUTICS LTD ALCOHOL ADDICTION PIPELINE DETAILS**

### 15.1 Chronos Therapeutics Ltd Business Profile

### 15.2 Chronos Therapeutics Ltd Alcohol Addiction Drug Details

### 15.3 Drug Snapshot

#### 15.3.1 Originator

#### 15.3.2 Collaborator/Co-Developer

#### 15.3.3 Route of Administration

#### 15.3.4 Orphan Drug/Fast Track/Special Designation

#### 15.3.5 Geography

#### 15.3.6 Type of Molecular Entity

#### 15.3.7 Current Status

### 15.4 Drug Overview

### 15.5 Drug Mechanism of Action

### 15.6 Clinical/Pre-clinical Trial Details

### 15.7 Latest Drug Developments

## **16 CORCEPT THERAPEUTICS INC ALCOHOL ADDICTION PIPELINE DETAILS**

### 16.1 Corcept Therapeutics Inc Business Profile

16.2 Corcept Therapeutics Inc Alcohol Addiction Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

## **17 CUREMARK LLC ALCOHOL ADDICTION PIPELINE DETAILS**

17.1 Curemark LLC Business Profile

17.2 Curemark LLC Alcohol Addiction Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

## **18 EPIVARIO INC ALCOHOL ADDICTION PIPELINE DETAILS**

18.1 EpiVario Inc Business Profile

18.2 EpiVario Inc Alcohol Addiction Drug Details

18.3 Drug Snapshot

18.3.1 Originator

18.3.2 Collaborator/Co-Developer

18.3.3 Route of Administration

- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19 ETHYPHARM SA ALCOHOL ADDICTION PIPELINE DETAILS**

- 19.1 Ethypharm SA Business Profile
- 19.2 Ethypharm SA Alcohol Addiction Drug Details
- 19.3 Drug Snapshot
  - 19.3.1 Originator
  - 19.3.2 Collaborator/Co-Developer
  - 19.3.3 Route of Administration
  - 19.3.4 Orphan Drug/Fast Track/Special Designation
  - 19.3.5 Geography
  - 19.3.6 Type of Molecular Entity
  - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20 H. LUNDBECK AS ALCOHOL ADDICTION PIPELINE DETAILS**

- 20.1 H. Lundbeck AS Business Profile
- 20.2 H. Lundbeck AS Alcohol Addiction Drug Details
- 20.3 Drug Snapshot
  - 20.3.1 Originator
  - 20.3.2 Collaborator/Co-Developer
  - 20.3.3 Route of Administration
  - 20.3.4 Orphan Drug/Fast Track/Special Designation
  - 20.3.5 Geography
  - 20.3.6 Type of Molecular Entity
  - 20.3.7 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21 HEPTARES THERAPEUTICS LTD ALCOHOL ADDICTION PIPELINE DETAILS**

- 21.1 Heptares Therapeutics Ltd Business Profile
- 21.2 Heptares Therapeutics Ltd Alcohol Addiction Drug Details
- 21.3 Drug Snapshot
  - 21.3.1 Originator
  - 21.3.2 Collaborator/Co-Developer
  - 21.3.3 Route of Administration
  - 21.3.4 Orphan Drug/Fast Track/Special Designation
  - 21.3.5 Geography
  - 21.3.6 Type of Molecular Entity
  - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22 INDIVIOR PLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 22.1 Indivior Plc Business Profile
- 22.2 Indivior Plc Alcohol Addiction Drug Details
- 22.3 Drug Snapshot
  - 22.3.1 Originator
  - 22.3.2 Collaborator/Co-Developer
  - 22.3.3 Route of Administration
  - 22.3.4 Orphan Drug/Fast Track/Special Designation
  - 22.3.5 Geography
  - 22.3.6 Type of Molecular Entity
  - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23 JOHNSON & JOHNSON ALCOHOL ADDICTION PIPELINE DETAILS**

- 23.1 Johnson & Johnson Business Profile
- 23.2 Johnson & Johnson Alcohol Addiction Drug Details
- 23.3 Drug Snapshot
  - 23.3.1 Originator
  - 23.3.2 Collaborator/Co-Developer
  - 23.3.3 Route of Administration
  - 23.3.4 Orphan Drug/Fast Track/Special Designation
  - 23.3.5 Geography
  - 23.3.6 Type of Molecular Entity
  - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24 KINNOV THERAPEUTICS SAS ALCOHOL ADDICTION PIPELINE DETAILS**

- 24.1 Kinnov Therapeutics SAS Business Profile
- 24.2 Kinnov Therapeutics SAS Alcohol Addiction Drug Details
- 24.3 Drug Snapshot
  - 24.3.1 Originator
  - 24.3.2 Collaborator/Co-Developer
  - 24.3.3 Route of Administration
  - 24.3.4 Orphan Drug/Fast Track/Special Designation
  - 24.3.5 Geography
  - 24.3.6 Type of Molecular Entity
  - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25 KYORIN PHARMACEUTICAL CO LTD ALCOHOL ADDICTION PIPELINE DETAILS**

- 25.1 Kyorin Pharmaceutical Co Ltd Business Profile
- 25.2 Kyorin Pharmaceutical Co Ltd Alcohol Addiction Drug Details
- 25.3 Drug Snapshot

- 25.3.1 Originator
- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

## **26 LABORATORIO FARMACEUTICO CT SRL ALCOHOL ADDICTION PIPELINE DETAILS**

- 26.1 Laboratorio Farmaceutico CT Srl Business Profile
- 26.2 Laboratorio Farmaceutico CT Srl Alcohol Addiction Drug Details
- 26.3 Drug Snapshot
  - 26.3.1 Originator
  - 26.3.2 Collaborator/Co-Developer
  - 26.3.3 Route of Administration
  - 26.3.4 Orphan Drug/Fast Track/Special Designation
  - 26.3.5 Geography
  - 26.3.6 Type of Molecular Entity
  - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

## **27 LOHOCLA RESEARCH CORP ALCOHOL ADDICTION PIPELINE DETAILS**

- 27.1 Lohocla Research Corp Business Profile
- 27.2 Lohocla Research Corp Alcohol Addiction Drug Details
- 27.3 Drug Snapshot
  - 27.3.1 Originator
  - 27.3.2 Collaborator/Co-Developer
  - 27.3.3 Route of Administration
  - 27.3.4 Orphan Drug/Fast Track/Special Designation

- 27.3.5 Geography
- 27.3.6 Type of Molecular Entity
- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

## **28 MAPREG SAS ALCOHOL ADDICTION PIPELINE DETAILS**

- 28.1 Mapreg SAS Business Profile
- 28.2 Mapreg SAS Alcohol Addiction Drug Details
- 28.3 Drug Snapshot
  - 28.3.1 Originator
  - 28.3.2 Collaborator/Co-Developer
  - 28.3.3 Route of Administration
  - 28.3.4 Orphan Drug/Fast Track/Special Designation
  - 28.3.5 Geography
  - 28.3.6 Type of Molecular Entity
  - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

## **29 MONTISERA LTD ALCOHOL ADDICTION PIPELINE DETAILS**

- 29.1 Montisera Ltd Business Profile
- 29.2 Montisera Ltd Alcohol Addiction Drug Details
- 29.3 Drug Snapshot
  - 29.3.1 Originator
  - 29.3.2 Collaborator/Co-Developer
  - 29.3.3 Route of Administration
  - 29.3.4 Orphan Drug/Fast Track/Special Designation
  - 29.3.5 Geography
  - 29.3.6 Type of Molecular Entity
  - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action



29.6 Clinical/Pre-clinical Trial Details

29.7 Latest Drug Developments

### **30 OMEROS CORP ALCOHOL ADDICTION PIPELINE DETAILS**

30.1 Omeros Corp Business Profile

30.2 Omeros Corp Alcohol Addiction Drug Details

30.3 Drug Snapshot

30.3.1 Originator

30.3.2 Collaborator/Co-Developer

30.3.3 Route of Administration

30.3.4 Orphan Drug/Fast Track/Special Designation

30.3.5 Geography

30.3.6 Type of Molecular Entity

30.3.7 Current Status

30.4 Drug Overview

30.5 Drug Mechanism of Action

30.6 Clinical/Pre-clinical Trial Details

30.7 Latest Drug Developments

### **31 POP TEST ONCOLOGY LLC ALCOHOL ADDICTION PIPELINE DETAILS**

31.1 Pop Test Oncology LLC Business Profile

31.2 Pop Test Oncology LLC Alcohol Addiction Drug Details

31.3 Drug Snapshot

31.3.1 Originator

31.3.2 Collaborator/Co-Developer

31.3.3 Route of Administration

31.3.4 Orphan Drug/Fast Track/Special Designation

31.3.5 Geography

31.3.6 Type of Molecular Entity

31.3.7 Current Status

31.4 Drug Overview

31.5 Drug Mechanism of Action

31.6 Clinical/Pre-clinical Trial Details

31.7 Latest Drug Developments

### **32 SAVANT HWP INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 32.1 Savant HWP Inc Business Profile
- 32.2 Savant HWP Inc Alcohol Addiction Drug Details
- 32.3 Drug Snapshot
  - 32.3.1 Originator
  - 32.3.2 Collaborator/Co-Developer
  - 32.3.3 Route of Administration
  - 32.3.4 Orphan Drug/Fast Track/Special Designation
  - 32.3.5 Geography
  - 32.3.6 Type of Molecular Entity
  - 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

### **33 SILENCE THERAPEUTICS PLC ALCOHOL ADDICTION PIPELINE DETAILS**

- 33.1 Silence Therapeutics Plc Business Profile
- 33.2 Silence Therapeutics Plc Alcohol Addiction Drug Details
- 33.3 Drug Snapshot
  - 33.3.1 Originator
  - 33.3.2 Collaborator/Co-Developer
  - 33.3.3 Route of Administration
  - 33.3.4 Orphan Drug/Fast Track/Special Designation
  - 33.3.5 Geography
  - 33.3.6 Type of Molecular Entity
  - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

### **34 SK BIOPHARMACEUTICALS CO LTD ALCOHOL ADDICTION PIPELINE DETAILS**

- 34.1 SK Biopharmaceuticals Co Ltd Business Profile
- 34.2 SK Biopharmaceuticals Co Ltd Alcohol Addiction Drug Details
- 34.3 Drug Snapshot
  - 34.3.1 Originator

- 34.3.2 Collaborator/Co-Developer
- 34.3.3 Route of Administration
- 34.3.4 Orphan Drug/Fast Track/Special Designation
- 34.3.5 Geography
- 34.3.6 Type of Molecular Entity
- 34.3.7 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

## **35 TONIX PHARMACEUTICALS HOLDING CORP ALCOHOL ADDICTION PIPELINE DETAILS**

- 35.1 Tonix Pharmaceuticals Holding Corp Business Profile
- 35.2 Tonix Pharmaceuticals Holding Corp Alcohol Addiction Drug Details
- 35.3 Drug Snapshot
  - 35.3.1 Originator
  - 35.3.2 Collaborator/Co-Developer
  - 35.3.3 Route of Administration
  - 35.3.4 Orphan Drug/Fast Track/Special Designation
  - 35.3.5 Geography
  - 35.3.6 Type of Molecular Entity
  - 35.3.7 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

## **36 VM DISCOVERY INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 36.1 VM Discovery Inc Business Profile
- 36.2 VM Discovery Inc Alcohol Addiction Drug Details
- 36.3 Drug Snapshot
  - 36.3.1 Originator
  - 36.3.2 Collaborator/Co-Developer
  - 36.3.3 Route of Administration
  - 36.3.4 Orphan Drug/Fast Track/Special Designation
  - 36.3.5 Geography

- 36.3.6 Type of Molecular Entity
- 36.3.7 Current Status
- 36.4 Drug Overview
- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

## **37 ZYNERBA PHARMACEUTICALS INC ALCOHOL ADDICTION PIPELINE DETAILS**

- 37.1 Zynerba Pharmaceuticals Inc Business Profile
- 37.2 Zynerba Pharmaceuticals Inc Alcohol Addiction Drug Details
- 37.3 Drug Snapshot
  - 37.3.1 Originator
  - 37.3.2 Collaborator/Co-Developer
  - 37.3.3 Route of Administration
  - 37.3.4 Orphan Drug/Fast Track/Special Designation
  - 37.3.5 Geography
  - 37.3.6 Type of Molecular Entity
  - 37.3.7 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

## **38. LATEST ALCOHOL ADDICTION DRUG PIPELINE DEVELOPMENTS, 2019**

### **39. APPENDIX**

- 39.1 About Us
- 39.2 Sources and Methodology
- 39.3 Contact Information

## I would like to order

Product name: 2019 Future of Alcohol Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/29BCFD1AE46EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/29BCFD1AE46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

